Guardant Health Q4 Earnings Call Highlights

Adjusted EBITDA loss narrowed to $64.9 million in Q4 from $78.4 million in the prior-year quarter. For the full year, adjusted EBITDA loss improved to $220.9 million versus $257.5 million in 2024.Management attributed the performance to “broad-based growth” across oncology, screening, and the biopharma and data segment. The company reported non-GAAP gross margin of 66% in Q4, up from 63% a year earlier, and 66% for the full year, up from 62% in 2024.Guardant said total revenue increased 39% year over year t ...